Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Pliant Therapeutics Inc.
PLRX | US
1.29
USD0
0%
PLRX | US
About Pliant Therapeutics Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
05/03/2026
Close
1.29
Open
1.29
High
1.30
Low
1.27
Pliant Therapeutics Inc. a clinical stage biopharmaceutical company discovers develops and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474 a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095 a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics Inc. was incorporated in 2015 and is based in South San Francisco California.
View LessPLRX | US
Risk
57.9
Sharpe
-0.14
Luna's Score
46/100
Recommendation
Hold
Luna says (PLRX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
41.2%1 month
57.9%3 months
56.9%6 months
62.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.27
Debt to equity
0.15
Debt to assets
0.12
Ent. to EBITDA
-2.54
Ent. to rev.
1.38K
PEG
-
Other Fundamentals
EBITDA
-205.71M
MarketCap
78.43M
MarketCap(USD)
78.43M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-40.06
Short ratio
19.72
Short perc.
11.37
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.12
Range1M
0.24
Range3M
0.58
Volumes: Market Activity
Rel. volume
0.29
Price X volume
273.00K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.54 | 0.53 | Cheaper |
| Ent. to Revenue | 1,376.69 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.27 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 56.91 | 72.80 | Lower Risk |
| Debt to Equity | 0.15 | -1.23 | Expensive |
| Debt to Assets | 0.12 | 0.25 | Cheaper |
| Market Cap | 78.43M | 3.66B | Emerging |
